The present invention relates to the technical field of
genetic engineering, and specifically relates to a ketoreductase
mutant and the use thereof. The ketoreductase
mutant has one or more
amino acid mutations as compared to the
amino acid sequence of a wild-type ketoreductase as shown in SEQ ID NO. 2, wherein the wild-type ketoreductase is derived from
Chryseobacterium sp. When a ketoreductase and a
mutant thereof are used in the resolution of a mirogabalin intermediate, the chiral purity of a target product is 99.9% or more. Compared with currently reported methods for synthesizing a target product, the use of the ketoreductase and the mutant thereof for target product synthesis avoids the use of a
metal catalyst, thereby making the process
environmentally friendly and reducing the cost. In addition, the ketoreductase mutant simplifies the resolution process steps while improving the chiral purity of a target product, resulting in a simple synthesis method.